secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001439222-23-000117
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q2 2023: PYRUKYND revenue $6.7M; net loss $83.8M; pipeline advances
-------------------------------------------------------------------------

- PYRUKYND net revenue $6.7M in Q2, up 20% QoQ; 147 patients completed enrollment forms, 99 on therapy.
- Net loss $83.8M vs $91.8M a year ago; cash $946.9M, expected runway into 2026.
- Phase 2 mitapivat in sickle cell positive; Phase 3 enrollment to begin Q4 2023.
- Completed enrollment in Phase 3 thalassemia studies (ENERGIZE/ENERGIZE-T) and Phase 2a AG-946 in LR-MDS.
- Licensed Alnylam siRNA for polycythemia vera; appointed Catherine Owens to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/0001439222-23-000117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922223000117/agio-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001439222-23-000117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer